PC
LIMNW

Periscope Capital’s Liminatus Pharma Warrants LIMNW Stock Holding History

Periscope Capital’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9K Hold
47,500
– – ﹤0.01% 423
2025
Q4 		$1.73K Hold
47,500
– – ﹤0.01% 344
2025
Q3 		$7.03K Sell
47,500
-2,500
-5% -$488 ﹤0.01% 275
2025
Q2 		$12K Buy
+50,000
New +$9.82K ﹤0.01% 210

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.4% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Periscope Capital's LIMNW Position: Q1 2026 in Review

Periscope Capital held its Liminatus Pharma Warrants (LIMNW) position steady in Q1 2026 at 47,500 shares worth $1.9K. The position accounts for ﹤0.01% of the portfolio, ranked #423.

Periscope Capital first reported a position in LIMNW in Q2 2025 and has held it in 4 quarters since. The position peaked at $12K in Q2 2025. 21 funds tracked by Wall St. Rank hold LIMNW as of Q1 2026.

  • Periscope Capital held 47,500 shares of Liminatus Pharma Warrants worth $1.9K as of Q1 2026.
  • Periscope Capital left its Liminatus Pharma Warrants share count unchanged in Q1 2026.
  • Liminatus Pharma Warrants made up ﹤0.01% of Periscope Capital's portfolio in Q1 2026, its #423 holding.
  • Periscope Capital first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 4 quarters since.
  • Periscope Capital's Liminatus Pharma Warrants position peaked at $12K in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q1 2026.

Based on Periscope Capital's 13F filing for Q1 2026, filed 14 May 2026.